BB-1709 for injection was approved for clinical practice

On January 28, 2023, Bristiscon Biopharmaceutical (Hangzhou) Co., Ltd. reported that the clinical trial application (IND) of BB-1709, the company's anti-tumor class 1 new drug antibody conjugate (ADC) BB-1709 was approved by the National Medical Products Administration (NMPA) of China (acceptance number: CXSL2200580). BB-1709 is a first-in-class innovative immunosuppressive target ADC with a wide range of solid tumor indications and global competitive potential. At the end of October 2022, BB-1709 has received FDA Phase I clinical trial approval in the United States. So far, Brixcon has three innovative ADCs in the clinical stage.

With a number of innovative drugs entering the clinic, the company has built a research and development site of more than 10,000 m² and a GMP production base that meets international standards in Hangzhou Pharmaceutical Port Town, which can meet the clinical batch and early marketing production needs of macromolecule innovative drugs. With the joint efforts of the Brix Scone team, BB-1709 is the company's first antibody and ADC stock solution completely in the self-built factory to complete the production project. The company has now built an international team to accelerate the application process, clinical research and commercialization of international innovative drug projects while continuously enriching the early R&D pipeline.

About Bristiscon

Bliss Biopharmaceutical (Hangzhou) Co., Ltd., established in December 2017 in Qiantang District, Hangzhou City, Zhejiang Province, is a national high-tech enterprise in the clinical stage of biomedical R&D with independent intellectual property rights, co-founded by a number of overseas returnees from the United States, focusing on the research and development and industrialization of anti-tumor biological innovative drugs. At present, the company has three innovative ADCs targeted for tumors in the clinical research stage, all of which have broad market prospects for a variety of tumor indications. The company's core team has successful experience in multiple product development and industrialization in this field, a variety of product technology platforms, rich drug gradient R&D pipelines, and the ability to produce antibodies and ADCs that meet international GMP standards in its own plants. Adhering to the company's core value concept of "gathering the power of hundreds of schools and the health of the public", Bailiscang works closely with domestic and foreign counterparts to jointly promote the research and development and industrialization of differentiated biological innovative drugs with international competitiveness.

On January 28, 2023, Bristiscon Biopharmaceutical (Hangzhou) Co., Ltd. reported that the clinical trial application (IND) of BB-1709, the company's anti-tumor class 1 new drug antibody conjugate (ADC) BB-1709 was approved by the National Medical Products Administration (NMPA) of China (acceptance number: CXSL2200580). BB-1709 is a first-in-class innovative immunosuppressive target ADC with a wide range of solid tumor indications and global competitive potential. At the end of October 2022, BB-1709 has received FDA Phase I clinical trial approval in the United States. So far, Brixcon has three innovative ADCs in the clinical stage.

With a number of innovative drugs entering the clinic, the company has built a research and development site of more than 10,000 m² and a GMP production base that meets international standards in Hangzhou Pharmaceutical Port Town, which can meet the clinical batch and early marketing production needs of macromolecule innovative drugs. With the joint efforts of the Brix Scone team, BB-1709 is the company's first antibody and ADC stock solution completely in the self-built factory to complete the production project. The company has now built an international team to accelerate the application process, clinical research and commercialization of international innovative drug projects while continuously enriching the early R&D pipeline.

About Bristiscon

Bliss Biopharmaceutical (Hangzhou) Co., Ltd., established in December 2017 in Qiantang District, Hangzhou City, Zhejiang Province, is a national high-tech enterprise in the clinical stage of biomedical R&D with independent intellectual property rights, co-founded by a number of overseas returnees from the United States, focusing on the research and development and industrialization of anti-tumor biological innovative drugs. At present, the company has three innovative ADCs targeted for tumors in the clinical research stage, all of which have broad market prospects for a variety of tumor indications. The company's core team has successful experience in multiple product development and industrialization in this field, a variety of product technology platforms, rich drug gradient R&D pipelines, and the ability to produce antibodies and ADCs that meet international GMP standards in its own plants. Adhering to the company's core value concept of "gathering the power of hundreds of schools and the health of the public", Bailiscang works closely with domestic and foreign counterparts to jointly promote the research and development and industrialization of differentiated biological innovative drugs with international competitiveness.